PMH53 Measuring Real World Outcomes by Incorporating PRO Data Collection into Patient Access Support Programs  by Stevens, C.A.
scriptive statistics were reported for psychiatrists’ sociodemographic and profes-
sional characteristics. Part-worth utilities were estimated using random effects
logit models, and relative importance values were calculated for the attributes.
RESULTS:Complete datawere available from478 psychiatrists; theirmean agewas
52.1 (9.4 SD) years, and the majority were male (n326; 68.2%) and Caucasian
(n354; 74.1%). The psychiatrists had a mean of 19.0 (9.1 SD) years’ experience
practicing psychiatry. Across all patient profiles, the efficacy attribute consistently
had the highest relative importance (RI): 54.93%. Mode of administration
(RI13.51%) and formulary access (RI11.33%) also contributed notably to the psy-
chiatrists’ medication preferences. Other attributes were of more minor impor-
tance, each with RI values 10%, including onset of action (RI6.95%), dosing fre-
quency (RI: oral6.23%; injection0.94%), safety (RI4.30%), and side effects
(RI1.80%). The RI of medication attributes showed some differences across pa-
tient profiles; mode of administration increased in importance for both types of
nonadherent patients, while formulary access and safety decreased in importance.
CONCLUSIONS: The results of the DCE suggest that efficacy is the most important
factor for psychiatrists’ making medication decisions regarding the treatment of
patients with schizophrenia. The RI of efficacy does not vary by patient profile;
however, the RI of other attributes tends to vary depending on the profile of the
patient being treated.
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OBJECTIVES: Identify attributes of patients with schizophrenia taking oral antip-
sychotics who state preference for monthly injectable antipsychotic therapy.
METHODS: From a 2007-2008 survey of patients self-reporting a schizophrenia
diagnosis (N1083), respondents currently using oral antipsychotics but not inject-
ables (N984) were classified as preferring monthly injectable antipsychotic ther-
apy if they answered “very likely” or “extremely likely” on a 5-point Likert scale to,
“If you could receive your medication once a month as an injection, instead of
having to take daily tablets or liquids, how likely would you be to choose the
injection?” (N268). The comparator group consisted of those who answered “not
at all likely” or “somewhat likely” (N485). Attributes were included in a single
logistic regression model with the dependent variable indicated by the preference
for monthly injectable antipsychotic therapy. Independent variables included de-
mographics, attitudes toward disease management, previous medication and
health care resource use, and self-reported adherence, asmeasured by theMorisky
Medication Adherence Scale (MMAS). RESULTS: Current oral antipsychotic users
classified as having low adherence (MMAS3 or 4) were 1.7 times more likely to
prefer monthly injectable antipsychotic therapy (p0.03) than those more adher-
ent. Respondents aged 35-54 years were 1.8 times more likely to prefer monthly
injectable antipsychotic therapy than respondents 55 years (p0.03). Respon-
dents who stated psychiatric medication was a “very important” or “extremely
important” aspect of their life were 2.0 times more likely to prefer monthly inject-
able antipsychotic therapy (p0.01) than those attaching less importance to their
medication. CONCLUSIONS: In this survey of patients with schizophrenia, those
who viewed their psychiatric medication as important and those who reported
lower adherence were more likely to prefer once-monthly injectable antipsychotic
therapy. These insights into patient attitudes and preferences can help mental
health care professionals effectively engage in shared decision making with their
patients. Support: Janssen Scientific Affairs, LLC.
PMH52
LEVOMILNACIPRAN IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER:
FUNCTIONAL HEALTH AND WELL-BEING EFFICACY RESULTS FROM A PHASE III
CLINICAL TRIAL
Blum SI1, Tourkodimitris S1, Ruth A2
1Forest Research Institute, Inc, Jersey City, NJ, USA, 2Prescott Medical Communications Group,
Chicago, IL, USA
OBJECTIVES: Levomilnacipran (1S, 2R-milnacipran) is a potent and selective sero-
tonin and norepinephrine reuptake inhibitor (SNRI) in clinical development for the
treatment ofmajor depressive disorder (MDD). Primary and post hoc analyseswere
conducted on data from a positive Phase III trial (NCT00969709) to evaluate the
functional health and well being of patients with MDD treated with sustained
released (SR) levomilnacipran. METHODS: A double-blind, multicenter, parallel-
group, placebo-controlled, fixed-dose study in patients aged 18-65 years who met
DSM-IV-TR criteria for MDD and Montgomery-Asberg Depression Rating Scale-
Clinician Rated (MADRS-CR) score 30. Study comprised a 1-week single-blind,
placebo lead-in, 8-week double-blind treatment, and 2-week double-blind down-
taper. Patients were randomized to placebo (n175) or once-daily levomilnacipran
(n529) 40 mg, 80 mg, or 120 mg (titrated-up from an initial dose of 20 mg). Func-
tional health and well being were measured using change from baseline toWeek 8
on the SF-36v2 acute (1-week recall) health survey. Individual health dimensions,
and physical (PCS) and mental (MCS) component summary scores were compared
for levomilnacipran and placebo (ITT population) using an ANCOVA model.
RESULTS: Patients in both groups had deficits in mental-health (baseline MCS
scores: (placebo, 17.29.2; levomilnacipran, 18.28.5); baseline PCS scores (PBO:
52.611.1; LVM: 51.111.1) were slightly higher than the population norm. Follow-
ing 8 weeks of treatment, levomilnacipran patients versus placebo demonstrated
significantly greater improvement in MCS (LSMD4.41.36; p.0013) and on sev-
eral individual dimensions (General Health [2.30.69; p.0007], Vitality [2.41.05,
p.0228], Social Functioning [3.11.17; p.0086], Role Emotional [3.11.20;
p.0097], Mental Health [4.31.16; p.0003]. Nonsignificant PCS [-0.20.74;
p.8386] and other dimension score changes were noted. CONCLUSIONS: Levom-
ilnacipran patients experienced statistically significant and clinically meaningful
improvements in functional health and well being as measured by the SF-36 MCS
and associated individual dimensions. Nonsignificant changes were noted for the
PCS and associated individual dimensions. Supported by funding from Forest Lab-
oratories, Inc.
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OBJECTIVES: The current focus on the use of real world data in evaluating out-
comes, drug value and in establishing payer coverage policies requires that data be
collected post regulatory approval. The costs involved in formal late phase com-
mitments and the challenge of getting health care providers to participate in data
collection programs like registries can prove overly burdensome and rate limiting.
The objective of this study is to determine if PROmeasures can be incorporated into
patient support programs to collect data that can demonstrate value and be pre-
sented to payers. METHODS: Many product sponsors establish a no cost and toll
free program to support patients navigate their insurance benefits and obtain ac-
cess to prescribe therapy. A total of 2000 opioid addicted patients were divided into
2 groups; 1000 patients were not aligned with clinical care support to monitor
patient reported outcomes and 1000 that reported outcomes data into the patient
support program. RESULTS: Patients who received support services that allowed
for the collection of PRO’s stayed on treatment longer than those who did not have
access to report outcomes. Patients in the reporting arm stayed on therapy on
average three months longer than the patients who did not report outcomes. Pa-
tients who stayed on therapy longer did not cost payers as much as those who
came off of therapy sooner. CONCLUSIONS: Product sponsor patient support pro-
grams can serve as a valuable tool to support the reporting and collecting of PRO
data. Such programs can contain an opt-in procedure to allow patients access to
PRO tools that can help manage their disease and track treatment outcomes. Such
data can then be analyzed and reported on to demonstrate product value and cost
effectiveness through Budget Impact Modeling (BIM) comparing the cost of care of
those who do not track PRO data vs. those who do not.
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OBJECTIVES: The goal of this study was to examine the impact of physical pain on
depression using longitudinal survey data for general population in the United
States. METHODS: This work employed two rounds of Medical Expenditure Panel
Survey (MEPS) fromyears 2008 and 2009. Depressionwasmeasured by frequency of
feeling depressed over the last 2 weeks, scaled by 0-not at all, 1-several days, 2-
more than half the days, and 3-nearly every day. Physical pain was measured by
severity of pain scaled by 1-not at all, 2-a little bit, 3- moderately, 4-quite a bit, and
5-extremely. People older than 18, who had reported severity of depressed mood
and recent physical pain, marriage status, family size, and highest education de-
greeswere included in the study. Only round 2 and round 4 of the surveywere used
since pain questions were only asked in these two rounds. The final panel con-
tained 21,257 observations, among which 46.32% and 45.34% reported pain limited
normal work in round 2 and round 4 respectively; 28.25% and 27.26% documented
depressedmood in round 2 and 4 respectively. Ordinary Least Squares (OLS), Linear
Mixed Effect Model (LME), generalized linear model (GLM) were used to examine
the impact of pain on depression. RESULTS: Comparedwith GLM and LME, the OLS
estimates were shown upward biased. GLM and LME both suggested that individ-
uals whose physical pain deteriorated to the next level from round 2 to round 4
would present a 0.16 (p0.0001) more depressed mood (based on 0-3 scale) on
average. Individuals perceived better health status,were older, richer,married, and
employed were less depressed. CONCLUSIONS: This work utilized a national rep-
resentative longitudinal data to examine the impact of physical pain on depres-
sion. Severity of pain and some individual characteristics were found significantly
affecting the severity of depression.
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OBJECTIVES: Attention-deficit/hyperactivity disorder (ADHD) is the most common
neurobehavioral disorder characterized by developmentally inappropriate levels
of inattention andhyperactivity. Previous literature suggests that, racial and ethnic
disparities continue to exist for several medical conditions. Some studies have
shown that such differences reduce when difference in family income, health in-
surance and such sociodemographic factors are taken into account. But, it has been
also documented that such differences may accentuate for specific type of disor-
der. Aim of this study was to determine any racial and ethnic differences and
weather such differences can be explained by child’s other health condition and
sociodemographic characteristics.METHODS: A nationally representative sample
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